Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Indicia Production Acquires Biotechnologie Appliquee

Published: Friday, March 22, 2013
Last Updated: Thursday, March 21, 2013
Bookmark and Share
The acquisition strengthens Indicia Production’s ability to subcontract the manufacture of ready-to-use media for microbiological testing.

Indicia Production has announced the acquisition of Biotechnologie Appliquee, based in Taden, in Cotes-d’Armor, France.

The financial terms of this buyout, completed at the end of February, have not been disclosed.

Biotechnologie Appliquee, with a turnover of EUR 500,000 in 2012 and four employees, provides contract manufacturing of ready-to-use media for microbiological testing to the food-processing, pharmaceutical and cosmetic industries.

The company is smaller and more flexible than Indicia Production with extensive expertise in subcontracting. It primarily provides low-volume manufacturing.

This acquisition therefore complements the range of mass-manufactured products from Indicia Production in Lyon.

Indicia Production can now provide contract services for both high and low volume manufacturing and can also respond to client requirements more quickly.

Indicia plans to secure new clients by expanding and diversifying its product range. The company also aims to draw on Biotechnologie Appliquee’s expertise to develop new products throughout 2013.

Ready-to-use culture media are used in the pharmaceutical industry as well as for microbiological diagnostics in food processing and environmental and water monitoring.

They are made from high-quality raw materials and use dehydrated bases selected in accordance with various standards. They are manufactured using advanced technology and are subject to quality testing by approved microbiologists.

“By joining with Indicia, we are able to expand our client base and offer a wider range of products,” said Jean-Yves Horvais, director of Biotechnologie Appliquee.

Horvais continued, “In return, Indicia brings its mass-manufacturing capacities and structured quality assurance. This will allow us to attract new companies within the industry.”

The acquisition enables Indicia Production to strengthen its position as a European leader in the manufacturing of ready-to-use media for microbiological testing.

Indicia is the first subcontractor to manufacture media pouches. The concept was developed at the site 15 years ago.

Biotechnologie Appliquee provides the newly formed company with a better understanding of the raw materials used in these media.

“With this acquisition, we hope to strengthen our production capacities and our subcontracting qualities for both high and low volume manufacturing,” said Stephane Legastelois, president and CEO of Indicia Production.

This buyout is part of Indicia Production’s growth strategy, which began in 2010, including the acquisition of new technologies to increase capacities for filling and sterilizing company media pouches.

Indicia Production, whose turnover reached EUR 5.1 million in 2012, expects a significant increase in profits over the next five years.

“The contract manufacturing market for microbiological testing and aseptic filling is booming. More industry professionals are now choosing to outsource these services in order to reduce their fixed costs,” said Stephane Legastelois. “They are also showing a keen interest in contract services, which we have just strengthened with this acquisition.”

A department manager is expected to join Indicia Production’s on-site team at Biotechnologie Appliquee, in Taden, in the second quarter of 2013.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos